
Experience
Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals
August 5, 2025
Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.
Related contacts
Related Practices & Industries
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
July 25, 2025
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Related contacts
Related Practices & Industries
Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 23, 2024
Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
Related contacts
Related Practices & Industries
Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion
November 26, 2024
Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.
Related contacts
Related Practices & Industries
Nerio Therapeutics Sells to Boehringer Ingelheim for up to $1.3 Billion
July 29, 2024
Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.
Related contacts
Related Practices & Industries
Related news and events
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
Admissions and credentials
California
Rankings and accolades
Winner, San Diego Business Journal: 40 Next Top Business Leaders Under Forty (2024)